Full record
Cass Review, 2024 (the UK’s independent review of youth gender clinics): the evidence for medicalizing children was remarkably weak. NHS England stopped routine puberty blockers for under-18s in March 2024. The enacted instrument is [S.I. 2024/1319](https://www.legislation.gov.uk/uksi/2024/1319/made) — the Medicines (Gonadotrophin-Releasing Hormone Analogues) (Emergency Prohibition) (England, Wales and Scotland) Order 2024, made 11 December 2024. Commission on Human Medicines: an “unacceptable safety risk.” Reviewed in 2027. Existing NHS patients already on the drugs were not cut off overnight. Wales aligned NHS GP prescribing in WSI 2024/774 (in force 19 July 2024). Scotland’s service redesign is a separate card — not this restriction.
The remaining path is a research trial, not routine care. PATHWAYS is NIHR- and NHS England-funded, sponsored by King’s College London and South London and Maudsley. 226 under-16s, randomised to immediate puberty blockers (GnRH analogues) or a one-year delay. MHRA signed off a modified protocol on 19 June 2026. On 31 July 2026 the High Court refused permission for judicial review; recruitment was planned from 1 August 2026. Cass found they do not have the evidence, so they are running an experiment to get it. Experimenting on kids in a trial is still experimenting. The puberty blockers trial is ongoing. The limit is on routine use — not a legislative ban. Queensland has said it will wait on this trial until at least 2031. See PATHWAYS news and Australia (Queensland).
Schools. From 1 September 2026, the revised Relationships Education, Relationships and Sex Education (RSE) and Health Education statutory guidance is in force in England (Education Act 2002 s.80A; Education Act 1996 s.403). Pupils are to be taught the facts and the law about biological sex and gender reassignment. Beyond those facts, schools must not endorse a particular view or teach gender identity as fact — they should not teach as fact that all people have a gender identity. That is a Schools restriction.